Vanesa Pytel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3601498/publications.pdf

Version: 2024-02-01

623734 580821 42 738 14 25 citations g-index h-index papers 44 44 44 1513 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Design and Verbal Fluency in Alzheimer's Disease and Frontotemporal Dementia: Clinical and Metabolic Correlates. Journal of the International Neuropsychological Society, 2022, 28, 947-962.	1.8	10
2	The Five-Point Test: Normative data for middle-aged and elderly Spaniards. Applied Neuropsychology Adult, 2022, 29, 1323-1331.	1.2	2
3	Identification of the main components of spontaneous speech in primary progressive aphasia and their neural underpinnings using multimodal MRI and FDG-PET imaging. Cortex, 2022, 146, 141-160.	2.4	9
4	Diagnosis of Alzheimer's disease and behavioural variant frontotemporal dementia with machine learningâ€∎ided neuropsychological assessment using feature engineering and genetic algorithms. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	16
5	Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimer's Disease and Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 711-722.	0.5	5
6	<i>ACE2, TMPRSS2</i> , and Furin variants and SARS oVâ€2 infection in Madrid, Spain. Journal of Medical Virology, 2021, 93, 863-869.	5.0	72
7	Whole-Exome Sequencing and C9orf72 Analysis in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 80, 985-990.	2.6	3
8	Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 5192.	4.1	4
9	Spanish Version of the Mini-Linguistic State Examination for the Diagnosis of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 83, 771-778.	2.6	6
10	Application of Machine Learning to Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. Brain Sciences, 2021, 11, 1262.	2.3	8
11	Genetic Algorithms for Optimized Diagnosis of Alzheimer's Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging. Frontiers in Aging Neuroscience, 2021, 13, 708932.	3.4	4
12	Diagnosis of Alzheimer's disease and frontotemporal dementia using FDGâ€PET: Application of genetic algorithms. Alzheimer's and Dementia, 2021, 17, .	0.8	2
13	Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months. Multiple Sclerosis and Related Disorders, 2020, 39, 101926.	2.0	16
14	Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. Brain and Behavior, 2020, 10, e01498.	2.2	40
15	Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 78, 537-541.	2.6	41
16	Reading prosody in the non-fluent and logopenic variants of primary progressive aphasia. Cortex, 2020, 132, 63-78.	2.4	12
17	Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis. CNS Neuroscience and Therapeutics, 2020, 26, 1178-1184.	3.9	4
18	Validation of the Spanish version of the Miniâ€Linguistic State Examination for the diagnosis of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e042817.	0.8	0

#	Article	IF	CITATIONS
19	Metabolic correlates of neuropsychological assessment in behavioral variant frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e044097.	0.8	0
20	Personalized repetitive transcranial magnetic stimulation for nonâ€fluent and semantic variants of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e047658.	0.8	0
21	Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task. Frontiers in Neurology, 2020, 11, 309.	2.4	5
22	Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Multiple Sclerosis and Related Disorders, 2020, 42, 102185.	2.0	118
23	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 2020, 44, 102297.	2.0	25
24	Amyloid <scp>Positron Emission Tomography</scp> in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damage. Annals of Neurology, 2020, 87, 988-988.	5.3	2
25	Validation of the Neuronorma battery for neuropsychological assessment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102070.	2.0	12
26	Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 629183.	2.4	17
27	Differences in age of diagnosis in familial multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 34, 91.	2.0	1
28	Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. Journal of Alzheimer's Disease, 2019, 72, 773-782.	2.6	10
29	Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's Disease: Clinical and FDG-PET Correlation. Journal of Alzheimer's Disease, 2019, 71, 1263-1269.	2.6	15
30	Repetitive transcranial magnetic stimulation in a case of atypical parkinsonism. Brain Stimulation, 2019, 12, 1343-1344.	1.6	0
31	Machine learning in the clinical and language characterisation of primary progressive aphasia variants. Cortex, 2019, 119, 312-323.	2.4	31
32	Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease. Frontiers in Neuroscience, 2019, 13, 302.	2.8	16
33	Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using wholeâ€exome next generation sequencing. Brain and Behavior, 2019, 9, e01272.	2.2	23
34	What is the meaning of PASAT rejection in multiple sclerosis?. Acta Neurologica Scandinavica, 2019, 139, 559-562.	2.1	9
35	Familial multiple sclerosis and association with other autoimmune diseases. Brain and Behavior, 2018, 8, e00899.	2.2	11
36	Conversion between Addenbrooke's Cognitive Examination III and Mini-Mental State Examination. International Psychogeriatrics, 2018, 30, 1227-1233.	1.0	17

#	Article	IF	CITATION
37	Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry. Frontiers in Neurology, 2018, 9, 920.	2.4	31
38	Structural MRI correlates of PASAT performance in multiple sclerosis. BMC Neurology, 2018, 18, 214.	1.8	20
39	Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. Frontiers in Aging Neuroscience, 2018, 10, 230.	3.4	22
40	Amyloid PET in pseudotumoral multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 15, 15-17.	2.0	7
41	Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. Frontiers in Neurology, 2017, 8, 643.	2.4	40
42	Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2050-2060.	6.4	48